ASSESSING COLORECTAL CANCER BY MEASURING HEMOGLOBIN AND M2-PK IN A STOOL SAMPLE

• US 20090075311A1
• Filed: 06/17/2008
• Published: 03/19/2009
• Est. Priority Date: 12/21/2005
• Status: Abandoned Application

• Current Assignee: Johann Karl
• Original Assignee: Johann Karl
• Inventors: Karl, Johann
• Application Number:
  US12/140,589
• Publication Number:
  US 20090075311A1
• Time in Patent Office: Days
• US Class Current: 435/15
• CPC Class Codes: G01N 2333/91215 with a definite EC number (2.7.1.-)
• CPC Class Codes: G01N 33/57419 of colon
• CPC Class Codes: G01N 33/721 Haemoglobin

Abstract

The present invention relates to a method aiding in the assessment of colorectal cancer. The method especially is used in assessing the absence or presence of colorectal cancer in vitro. The method is, for example, practiced by analyzing biochemical markers, comprising measuring in a stool sample the concentration of hemoglobin and M2-PK and correlating the concentrations determined to the absence or presence of colorectal cancer. To further improve the assessment of colorectal cancer in a method of this invention the level of one or more additional marker may be determined together with hemoglobin and M2-PK in a stool sample and be correlated to the absence or presence of colorectal cancer. The invention also relates to the use of a marker panel comprising hemoglobin and M2-PK in the early diagnosis of colorectal cancer, and it teaches a kit for performing the method of the invention.

Claims

1. A method for assessing in vitro the absence or presence of colorectal cancer in a patient, the method comprising

providing a stool sample from the patient,

measuring in the sample a concentration of hemoglobin and a concentration of pyruvate kinase isoform M2 (M2-PK), and

correlating the concentrations measured to the concentrations of hemoglobin and M2-PK known to be associated with the absence or presence of colorectal cancer in a population.

2. The method of claim 1, further comprising the steps of measuring a concentration of a marker selected from the group consisting of carcinoembryonic antigen (CEA), a soluble fragment of cytokeratin 19 (CYFRA 21-1), carbohydrate antigen 19-9 (CA19-9), carbohydrate antigen 724 (CA72-4), nicotinamide N-methyltransferase (NNMT), pyrroline-5-carboxylate reductase (PROC), and S-adenosylhomocysteine hydrolase (SAHH) and correlating the concentration of the marker to a concentration of the marker known to be associated with the absence or presence of colorectal cancer in a population.

3. The method of claim 2 wherein the marker is SAHH.

4. A kit for performing the method of claim 1 comprising the reagents required to specifically measure hemoglobin and M2-PK in a stool sample from a patient.